Medically reviewed by Doru Paul, MD Key Takeaways A JAK2 mutation can make your body produce too many blood cells.  JAK2 ...

Chronic myeloid leukaemia (CML) is a paradigmatic clonal disorder primarily driven by the BCR-ABL translocation, which produces a constitutively active tyrosine kinase. Traditionally, this genetic ...

The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive ...

The history of primary myelofibrosis dates back to 1951 and the description of four distinct clinicopathologic entities that came to be known as myeloproliferative neoplasms (MPNs): chronic myeloid ...

The JAK2 gene is a protein-coding gene of the Janus kinase family. It plays a role in cellular signaling. Evidence notes connections between this gene and some medical conditions. Variations in this ...

Myeloproliferative neoplasms (MPNs) represent a cluster of conditions characterized by the excessive production of blood cells within the bone marrow. Among MPN patients, abnormal quantities of red ...

While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jain: Wonderful.

Scientists have created a new technique that can assess how mutations in the genome influence the packaging of DNA in cells. The genome is massive, and has to be carefully wrapped around proteins so ...

Researchers from Bulgaria conduct an analysis of the potential for therapeutic vaccines in by comparing testing results for patients from their country with an international data set. Mutations may ...

Series B funds will enable clinical development of ATV-1601, an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary ...